ID   GGT1_HUMAN              Reviewed;         569 AA.
AC   P19440; Q08247; Q14404; Q8TBS1; Q9UMK1;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   02-JUN-2021, entry version 223.
DE   RecName: Full=Glutathione hydrolase 1 proenzyme;
DE            EC=3.4.19.13 {ECO:0000269|PubMed:17924658, ECO:0000269|PubMed:21447318};
DE   AltName: Full=Gamma-glutamyltransferase 1;
DE   AltName: Full=Gamma-glutamyltranspeptidase 1;
DE            Short=GGT 1;
DE            EC=2.3.2.2 {ECO:0000269|PubMed:17924658, ECO:0000269|PubMed:21447318, ECO:0000269|PubMed:23682772, ECO:0000269|PubMed:7673200, ECO:0000269|PubMed:7759490, ECO:0000269|PubMed:8095045, ECO:0000269|PubMed:8827453};
DE   AltName: Full=Leukotriene-C4 hydrolase;
DE            EC=3.4.19.14 {ECO:0000269|PubMed:21447318};
DE   AltName: CD_antigen=CD224;
DE   Contains:
DE     RecName: Full=Glutathione hydrolase 1 heavy chain;
DE   Contains:
DE     RecName: Full=Glutathione hydrolase 1 light chain;
DE   Flags: Precursor;
GN   Name=GGT1; Synonyms=GGT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-272.
RC   TISSUE=Placenta;
RX   PubMed=2904146; DOI=10.1073/pnas.85.23.8840;
RA   Rajpert-De Meyts E., Heisterkamp N., Groffen J.;
RT   "Cloning and nucleotide sequence of human gamma-glutamyl transpeptidase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:8840-8844(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 30-58 AND
RP   381-408, AND VARIANT ALA-272.
RC   TISSUE=Kidney, and Liver;
RX   PubMed=2907498; DOI=10.1016/0378-1119(88)90307-1;
RA   Sakamuro D., Yamazoe M., Matsuda Y., Kangawa K., Taniguchi N., Matsuo H.,
RA   Yoshikawa H., Ogasawara N.;
RT   "The primary structure of human gamma-glutamyl transpeptidase.";
RL   Gene 73:1-9(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-272.
RX   PubMed=2563599; DOI=10.1016/0041-008x(89)90052-5;
RA   Pitot H.C., Goodspeed D.C., Dunn T.J., Hendrich S., Maronpot R.R.,
RA   Moran S.;
RT   "Regulation of the expression of some genes for enzymes of glutathione
RT   metabolism in hepatotoxicity and hepatocarcinogenesis.";
RL   Toxicol. Appl. Pharmacol. 97:23-34(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-272.
RC   TISSUE=Hepatoblastoma;
RX   PubMed=2568315; DOI=10.1016/0378-1119(89)90002-4;
RA   Goodspeed D.C., Dunn T.J., Miller C.D., Pitot H.C.;
RT   "Human gamma-glutamyl transpeptidase cDNA: comparison of hepatoma and
RT   kidney mRNA in the human and rat.";
RL   Gene 76:1-9(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT ALA-272.
RC   TISSUE=Liver;
RX   PubMed=1968061;
RA   Pawlak A., Cohen E.H., Octave J.-N., Schweickhardt R., Wu S.-J., Bulle F.,
RA   Chikhi N., Baik J.-H., Siegrist S., Guellaen G.;
RT   "An alternatively processed mRNA specific for gamma-glutamyl transpeptidase
RT   in human tissues.";
RL   J. Biol. Chem. 265:3256-3262(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-272.
RC   TISSUE=Pancreas;
RX   PubMed=1378736; DOI=10.1016/0006-2952(92)90140-e;
RA   Courtay C., Oster T., Michelet F., Visvikis A., Diederich M., Wellman M.,
RA   Siest G.;
RT   "Gamma-glutamyltransferase: nucleotide sequence of the human pancreatic
RT   cDNA. Evidence for a ubiquitous gamma-glutamyltransferase polypeptide in
RT   human tissues.";
RL   Biochem. Pharmacol. 43:2527-2533(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), LACK OF FUNCTION OF ISOFORM 3, AND
RP   TISSUE SPECIFICITY (ISOFORM 3).
RC   TISSUE=Lung;
RX   PubMed=7689219; DOI=10.1073/pnas.90.16.7461;
RA   Wetmore L.A., Gerard C., Drazen J.M.;
RT   "Human lung expresses unique gamma-glutamyl transpeptidase transcripts.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7461-7465(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 30-48 AND 381-403.
RC   TISSUE=Kidney;
RX   PubMed=2896486; DOI=10.1016/0003-9861(88)90390-6;
RA   Tate S.S., Khadse V., Wellner D.;
RT   "Renal gamma-glutamyl transpeptidases: structural and immunological
RT   studies.";
RL   Arch. Biochem. Biophys. 262:397-408(1988).
RN   [12]
RP   ALTERNATIVE SPLICING, AND ALTERNATIVE PROMOTER USAGE.
RX   PubMed=10392451; DOI=10.1016/s0305-0491(99)00013-9;
RA   Chikhi N., Holic N., Guellaen G., Laperche Y.;
RT   "Gamma-glutamyl transpeptidase gene organization and expression: a
RT   comparative analysis in rat, mouse, pig and human species.";
RL   Comp. Biochem. Physiol. 122B:367-380(1999).
RN   [13]
RP   GLYCOSYLATION, AND SIALIC ACID CONTENT.
RC   TISSUE=Kidney;
RX   PubMed=19463;
RA   Tate S.S., Ross M.E.;
RT   "Human kidney gamma-glutamyl transpeptidase. Catalytic properties, subunit
RT   structure, and localization of the gamma-glutamyl binding site on the light
RT   subunit.";
RL   J. Biol. Chem. 252:6042-6045(1977).
RN   [14]
RP   GLYCOSYLATION.
RX   PubMed=2900635; DOI=10.1016/0006-291x(88)90263-x;
RA   Tate S.S., Galbraith R.A.;
RT   "In vitro translation and processing of human hepatoma cell (Hep G2) gamma-
RT   glutamyl transpeptidase.";
RL   Biochem. Biophys. Res. Commun. 154:1167-1173(1988).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOCATALYTIC CLEAVAGE, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-100; GLU-102; ARG-107; GLU-108; ARG-112;
RP   ARG-139; ARG-147 AND ARG-150.
RX   PubMed=8095045;
RA   Ikeda Y., Fujii J., Taniguchi N.;
RT   "Significance of Arg-107 and Glu-108 in the catalytic mechanism of human
RT   gamma-glutamyl transpeptidase. Identification by site-directed
RT   mutagenesis.";
RL   J. Biol. Chem. 268:3980-3985(1993).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-422; ASP-423 AND CYS-454,
RP   AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=7759490; DOI=10.1074/jbc.270.21.12471;
RA   Ikeda Y., Fujii J., Taniguchi N., Meister A.;
RT   "Human gamma-glutamyl transpeptidase mutants involving conserved aspartate
RT   residues and the unique cysteine residue of the light subunit.";
RL   J. Biol. Chem. 270:12471-12475(1995).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF SER-385; SER-413; SER-425;
RP   SER-451 AND SER-452.
RX   PubMed=7673200; DOI=10.1074/jbc.270.38.22223;
RA   Ikeda Y., Fujii J., Anderson M.E., Taniguchi N., Meister A.;
RT   "Involvement of Ser-451 and Ser-452 in the catalysis of human gamma-
RT   glutamyl transpeptidase.";
RL   J. Biol. Chem. 270:22223-22228(1995).
RN   [18]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-383 AND HIS-505.
RX   PubMed=8827453; DOI=10.1093/oxfordjournals.jbchem.a021363;
RA   Ikeda Y., Fujii J., Taniguchi N.;
RT   "Effects of substitutions of the conserved histidine residues in human
RT   gamma-glutamyl transpeptidase.";
RL   J. Biochem. 119:1166-1170(1996).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-511.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.m400015-mcp200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H., Thuluvath P.J.,
RA   Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [20]
RP   CATALYTIC ACTIVITY, ACTIVE SITE, GLYCOSYLATION AT ASN-120; ASN-266; ASN-344
RP   AND ASN-511, IDENTIFICATION BY MASS SPECTROMETRY, AND FUNCTION.
RX   PubMed=17924658; DOI=10.1021/bi700956c;
RA   Castonguay R., Halim D., Morin M., Furtos A., Lherbet C., Bonneil E.,
RA   Thibault P., Keillor J.W.;
RT   "Kinetic characterization and identification of the acylation and
RT   glycosylation sites of recombinant human gamma-glutamyltranspeptidase.";
RL   Biochemistry 46:12253-12262(2007).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-120; ASN-230 AND ASN-511.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-120.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [23]
RP   GLYCOSYLATION AT ASN-95; ASN-120; ASN-230; ASN-266; ASN-297; ASN-344 AND
RP   ASN-511.
RX   PubMed=20622017; DOI=10.1074/jbc.m110.145938;
RA   West M.B., Segu Z.M., Feasley C.L., Kang P., Klouckova I., Li C.,
RA   Novotny M.V., West C.M., Mechref Y., Hanigan M.H.;
RT   "Analysis of site-specific glycosylation of renal and hepatic gamma-
RT   glutamyl transpeptidase from normal human tissue.";
RL   J. Biol. Chem. 285:29511-29524(2010).
RN   [24]
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE
RP   SPECIFICITY, AND ACTIVITY REGULATION.
RX   PubMed=21447318; DOI=10.1016/j.ab.2011.03.026;
RA   Wickham S., West M.B., Cook P.F., Hanigan M.H.;
RT   "Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl
RT   transpeptidase enzymes.";
RL   Anal. Biochem. 414:208-214(2011).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOCATALYTIC CLEAVAGE, ACTIVITY REGULATION,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AND MUTAGENESIS OF CYS-192 AND
RP   GLU-193.
RX   PubMed=23682772; DOI=10.1089/ars.2012.4997;
RA   West M.B., Wickham S., Parks E.E., Sherry D.M., Hanigan M.H.;
RT   "Human GGT2 does not autocleave into a functional enzyme: a cautionary tale
RT   for interpretation of microarray data on redox signaling.";
RL   Antioxid. Redox Signal. 19:1877-1888(2013).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) IN COMPLEX WITH GLUTAMATE AND
RP   CHLORIDE IONS, FUNCTION, CATALYTIC ACTIVITY, AUTOCATALYTIC CLEAVAGE,
RP   SUBUNIT, MUTAGENESIS OF GLN-545, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-95; ASN-120; ASN-230; ASN-266; ASN-344 AND ASN-511.
RX   PubMed=24047895; DOI=10.1074/jbc.m113.498139;
RA   West M.B., Chen Y., Wickham S., Heroux A., Cahill K., Hanigan M.H.,
RA   Mooers B.H.;
RT   "Novel insights into eukaryotic gamma-glutamyl transpeptidase 1 from the
RT   crystal structure of the glutamate-bound human enzyme.";
RL   J. Biol. Chem. 288:31902-31913(2013).
RN   [27] {ECO:0007744|PDB:4Z9O, ECO:0007744|PDB:4ZBK, ECO:0007744|PDB:4ZC6, ECO:0007744|PDB:4ZCG}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH SERINE-BORATE AND
RP   GLUTAMATE, AND GLYCOSYLATION AT ASN-95; ASN-120; ASN-230; ASN-266; ASN-344
RP   AND ASN-511.
RX   PubMed=26013825; DOI=10.1074/jbc.m115.659680;
RA   Terzyan S.S., Burgett A.W., Heroux A., Smith C.A., Mooers B.H.,
RA   Hanigan M.H.;
RT   "Human gamma-Glutamyl Transpeptidase 1: Structures of the free enzyme,
RT   inhibitor-bound tetrahedral transition states, and glutamate-bound enzyme
RT   reveal novel movement within the active site during catalysis.";
RL   J. Biol. Chem. 290:17576-17586(2015).
RN   [28]
RP   INVOLVEMENT IN GLUTH.
RX   PubMed=29483667; DOI=10.1038/s41431-018-0122-6;
RA   Darin N., Leckstroem K., Sikora P., Lindgren J., Almen G., Asin-Cayuela J.;
RT   "Gamma-glutamyl transpeptidase deficiency caused by a large homozygous
RT   intragenic deletion in GGT1.";
RL   Eur. J. Hum. Genet. 26:808-817(2018).
CC   -!- FUNCTION: Cleaves the gamma-glutamyl bond of extracellular glutathione
CC       (gamma-Glu-Cys-Gly), glutathione conjugates and other gamma-glutamyl
CC       compounds, such as leukotriene C4 (LTC4). The metabolism of glutathione
CC       by GGT1 releases free glutamate and the dipeptide cysteinyl-glycine,
CC       which is hydrolyzed to cysteine and glycine by dipeptidases. In the
CC       presence of high concentrations of dipeptides and some amino acids, can
CC       also catalyze a transpeptidation reaction, transferring the gamma-
CC       glutamyl moiety to an acceptor amino acid to form a new gamma-glutamyl
CC       compound (PubMed:17924658, PubMed:7673200, PubMed:7759490,
CC       PubMed:8095045, PubMed:8827453, PubMed:21447318). Contributes to
CC       cysteine homeostasis, glutathione homeostasis and in the conversion of
CC       the leukotriene LTC4 to LTD4. {ECO:0000269|PubMed:17924658,
CC       ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:21447318,
CC       ECO:0000269|PubMed:24047895, ECO:0000269|PubMed:7673200,
CC       ECO:0000269|PubMed:7759490, ECO:0000269|PubMed:8095045,
CC       ECO:0000269|PubMed:8827453}.
CC   -!- FUNCTION: [Isoform 3]: Seems to be inactive.
CC       {ECO:0000269|PubMed:7689219}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an alpha-amino acid + an N-terminal (5-L-glutamyl)-[peptide] =
CC         5-L-glutamyl amino acid + N-terminal L-alpha-aminoacyl-[peptide];
CC         Xref=Rhea:RHEA:23904, Rhea:RHEA-COMP:9780, Rhea:RHEA-COMP:9795,
CC         ChEBI:CHEBI:77644, ChEBI:CHEBI:78597, ChEBI:CHEBI:78599,
CC         ChEBI:CHEBI:78608; EC=2.3.2.2; Evidence={ECO:0000269|PubMed:17924658,
CC         ECO:0000269|PubMed:21447318, ECO:0000269|PubMed:23682772,
CC         ECO:0000269|PubMed:7673200, ECO:0000269|PubMed:7759490,
CC         ECO:0000269|PubMed:8095045, ECO:0000269|PubMed:8827453};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutathione + H2O = L-cysteinylglycine + L-glutamate;
CC         Xref=Rhea:RHEA:28807, ChEBI:CHEBI:15377, ChEBI:CHEBI:29985,
CC         ChEBI:CHEBI:57925, ChEBI:CHEBI:61694; EC=3.4.19.13;
CC         Evidence={ECO:0000269|PubMed:17924658, ECO:0000269|PubMed:21447318};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:28808;
CC         Evidence={ECO:0000305|PubMed:21447318};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an S-substituted glutathione + H2O = an S-substituted L-
CC         cysteinylglycine + L-glutamate; Xref=Rhea:RHEA:59468,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:29985, ChEBI:CHEBI:90779,
CC         ChEBI:CHEBI:143103; EC=3.4.19.13;
CC         Evidence={ECO:0000269|PubMed:17924658, ECO:0000269|PubMed:21447318};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:59469;
CC         Evidence={ECO:0000305|PubMed:21447318};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + leukotriene C4 = L-glutamate + leukotriene D4;
CC         Xref=Rhea:RHEA:31563, ChEBI:CHEBI:15377, ChEBI:CHEBI:29985,
CC         ChEBI:CHEBI:57973, ChEBI:CHEBI:63166; EC=3.4.19.14;
CC         Evidence={ECO:0000269|PubMed:21447318};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:31564;
CC         Evidence={ECO:0000305};
CC   -!- ACTIVITY REGULATION: Activated by autocatalytic cleavage
CC       (PubMed:23682772). Inhibited by serine-borate (PubMed:21447318).
CC       {ECO:0000269|PubMed:21447318, ECO:0000269|PubMed:23682772}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=11 mM for glycylglycine {ECO:0000269|PubMed:7759490};
CC         KM=10.6 uM for glutathione {ECO:0000269|PubMed:21447318};
CC         KM=8.8 uM for oxidized-glutathione {ECO:0000269|PubMed:21447318};
CC         KM=1.3 mM for D-gamma-glutamyl-p-nitroanalide
CC         {ECO:0000269|PubMed:7759490};
CC         KM=9.9 uM for S-methylglutathion {ECO:0000269|PubMed:21447318};
CC         KM=33.4 uM for gamma-glutamyl leucine {ECO:0000269|PubMed:21447318};
CC         KM=10.8 uM for leukotriene C4 {ECO:0000269|PubMed:21447318};
CC   -!- PATHWAY: Lipid metabolism; leukotriene D4 biosynthesis.
CC       {ECO:0000269|PubMed:21447318}.
CC   -!- PATHWAY: Sulfur metabolism; glutathione metabolism.
CC       {ECO:0000269|PubMed:21447318}.
CC   -!- SUBUNIT: Heterodimer composed of the light and heavy chains. The active
CC       site is located in the light chain. {ECO:0000269|PubMed:24047895,
CC       ECO:0000269|PubMed:8095045}.
CC   -!- INTERACTION:
CC       P19440-3; Q92993: KAT5; NbExp=3; IntAct=EBI-21558069, EBI-399080;
CC       P19440-3; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-21558069, EBI-11742507;
CC       P19440-3; P17252: PRKCA; NbExp=3; IntAct=EBI-21558069, EBI-1383528;
CC       P19440-3; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-21558069, EBI-9090795;
CC       P19440-3; P61981: YWHAG; NbExp=3; IntAct=EBI-21558069, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23682772,
CC       ECO:0000269|PubMed:8095045}; Single-pass type II membrane protein
CC       {ECO:0000250|UniProtKB:P07314}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P19440-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19440-2; Sequence=VSP_001746, VSP_001747;
CC       Name=3;
CC         IsoId=P19440-3; Sequence=VSP_008132;
CC   -!- TISSUE SPECIFICITY: Detected in fetal and adult kidney and liver, adult
CC       pancreas, stomach, intestine, placenta and lung. There are several
CC       other tissue-specific forms that arise from alternative promoter usage
CC       but that produce the same protein.
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: Lung-specific.
CC       {ECO:0000269|PubMed:7689219}.
CC   -!- PTM: N-glycosylated on both chains. Contains hexoses, hexosamines and
CC       sialic acid residues. Glycosylation profiles tested in kidney and liver
CC       tissues reveal the presence of tissue-specific and site-specific glycan
CC       composition, despite the overlap in composition among the N-glycans. A
CC       total of 36 glycan compositions, with 40 unique structures are
CC       observed. Up to 15 different glycans are observed at a single site,
CC       with site-specific variation in glycan composition. The difference in
CC       glycosylation profiles in the 2 tissues do not affect the enzyme
CC       activity. {ECO:0000269|PubMed:15084671, ECO:0000269|PubMed:17924658,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
CC       ECO:0000269|PubMed:19463, ECO:0000269|PubMed:20622017,
CC       ECO:0000269|PubMed:23682772, ECO:0000269|PubMed:24047895,
CC       ECO:0000269|PubMed:2900635}.
CC   -!- PTM: Cleaved by autocatalysis into a large and a small subunit and the
CC       autocatalytic cleavage is essential to the functional activation of the
CC       enzyme. {ECO:0000269|PubMed:23682772}.
CC   -!- DISEASE: Glutathionuria (GLUTH) [MIM:231950]: A very rare, autosomal
CC       recessive metabolic disorder characterized by the presence of
CC       glutathione in the urine, due to generalized gamma-glutamyl
CC       transpeptidase deficiency. Most patients manifest mild to moderate
CC       mental retardation, and behavioral disturbance. Seizures, tremor,
CC       marfanoid features and strabismus are observed in some patients.
CC       {ECO:0000269|PubMed:29483667}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. A large homozygous
CC       deletion that removes several exons of all isoforms of GGT1 has been
CC       found in one family affected by glutathionuria.
CC       {ECO:0000269|PubMed:29483667}.
CC   -!- MISCELLANEOUS: Cys-454 was thought to bind the gamma-glutamyl moiety,
CC       but mutagenesis of this residue had no effect on activity.
CC       {ECO:0000269|PubMed:7759490}.
CC   -!- MISCELLANEOUS: Chloride ions bound in the active site cavity may
CC       contribute to stabilize the protein fold.
CC       {ECO:0000305|PubMed:24047895}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the gamma-glutamyltransferase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35899.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Gamma-glutamyl transpeptidase entry;
CC       URL="https://en.wikipedia.org/wiki/Gamma_glutamyl_transpeptidase";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04131; AAA52547.1; -; mRNA.
DR   EMBL; M24087; AAA35899.1; ALT_INIT; mRNA.
DR   EMBL; M24903; AAA52546.1; -; mRNA.
DR   EMBL; J05235; AAA35889.1; -; mRNA.
DR   EMBL; X60069; CAA42674.1; -; mRNA.
DR   EMBL; L20490; AAA02884.1; -; mRNA.
DR   EMBL; L20493; AAA02886.1; -; mRNA.
DR   EMBL; CR456494; CAG30380.1; -; mRNA.
DR   EMBL; AP000356; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC025927; AAH25927.1; -; mRNA.
DR   EMBL; BC069473; AAH69473.1; -; mRNA.
DR   EMBL; BC069504; AAH69504.1; -; mRNA.
DR   EMBL; BC128238; AAI28239.1; -; mRNA.
DR   EMBL; BC128239; AAI28240.1; -; mRNA.
DR   CCDS; CCDS42992.1; -. [P19440-1]
DR   PIR; A31253; EKHUEX.
DR   PIR; A48987; A48987.
DR   PIR; A60439; A60439.
DR   PIR; JS0067; JS0067.
DR   PIR; PS0312; PS0312.
DR   RefSeq; NP_001275762.1; NM_001288833.1. [P19440-1]
DR   RefSeq; NP_038265.2; NM_013421.2. [P19440-1]
DR   RefSeq; NP_038347.2; NM_013430.2. [P19440-1]
DR   PDB; 4GDX; X-ray; 1.67 A; A=2-374, B=375-569.
DR   PDB; 4GG2; X-ray; 2.21 A; A=28-380, B=381-569.
DR   PDB; 4Z9O; X-ray; 2.30 A; A=28-380, B=381-569.
DR   PDB; 4ZBK; X-ray; 2.18 A; A=28-380, B=381-569.
DR   PDB; 4ZC6; X-ray; 2.10 A; A=28-380, B=381-569.
DR   PDB; 4ZCG; X-ray; 2.22 A; A=28-380, B=381-569.
DR   PDB; 5V4Q; X-ray; 2.20 A; A=28-380, B=381-569.
DR   PDBsum; 4GDX; -.
DR   PDBsum; 4GG2; -.
DR   PDBsum; 4Z9O; -.
DR   PDBsum; 4ZBK; -.
DR   PDBsum; 4ZC6; -.
DR   PDBsum; 4ZCG; -.
DR   PDBsum; 5V4Q; -.
DR   SMR; P19440; -.
DR   BioGRID; 108946; 12.
DR   IntAct; P19440; 11.
DR   MINT; P19440; -.
DR   STRING; 9606.ENSP00000383232; -.
DR   BindingDB; P19440; -.
DR   ChEMBL; CHEMBL5696; -.
DR   DrugBank; DB00143; Glutathione.
DR   DrugCentral; P19440; -.
DR   SwissLipids; SLP:000001454; -.
DR   MEROPS; T03.006; -.
DR   GlyConnect; 1261; 27 N-Linked glycans (4 sites).
DR   GlyGen; P19440; 7 sites.
DR   iPTMnet; P19440; -.
DR   PhosphoSitePlus; P19440; -.
DR   BioMuta; GGT1; -.
DR   DMDM; 93140064; -.
DR   CPTAC; CPTAC-2217; -.
DR   EPD; P19440; -.
DR   jPOST; P19440; -.
DR   MassIVE; P19440; -.
DR   MaxQB; P19440; -.
DR   PaxDb; P19440; -.
DR   PeptideAtlas; P19440; -.
DR   PRIDE; P19440; -.
DR   ProteomicsDB; 53662; -. [P19440-1]
DR   ProteomicsDB; 53663; -. [P19440-2]
DR   ProteomicsDB; 53664; -. [P19440-3]
DR   Antibodypedia; 24014; 457 antibodies.
DR   DNASU; 2678; -.
DR   Ensembl; ENST00000400380; ENSP00000383231; ENSG00000100031. [P19440-1]
DR   Ensembl; ENST00000400382; ENSP00000383232; ENSG00000100031. [P19440-1]
DR   Ensembl; ENST00000401885; ENSP00000384381; ENSG00000100031. [P19440-3]
DR   Ensembl; ENST00000403838; ENSP00000384820; ENSG00000100031. [P19440-3]
DR   Ensembl; ENST00000404532; ENSP00000385445; ENSG00000100031. [P19440-3]
DR   Ensembl; ENST00000425895; ENSP00000387499; ENSG00000100031. [P19440-2]
DR   GeneID; 2678; -.
DR   KEGG; hsa:2678; -.
DR   UCSC; uc003aan.2; human. [P19440-1]
DR   CTD; 2678; -.
DR   DisGeNET; 2678; -.
DR   GeneCards; GGT1; -.
DR   GeneReviews; GGT1; -.
DR   HGNC; HGNC:4250; GGT1.
DR   HPA; ENSG00000100031; Tissue enhanced (kidney, seminal vesicle).
DR   MalaCards; GGT1; -.
DR   MIM; 231950; phenotype.
DR   MIM; 612346; gene.
DR   neXtProt; NX_P19440; -.
DR   OpenTargets; ENSG00000100031; -.
DR   Orphanet; 33573; Gamma-glutamyl transpeptidase deficiency.
DR   PharmGKB; PA28662; -.
DR   VEuPathDB; HostDB:ENSG00000100031.18; -.
DR   eggNOG; KOG2410; Eukaryota.
DR   GeneTree; ENSGT00940000154601; -.
DR   HOGENOM; CLU_014813_1_3_1; -.
DR   InParanoid; P19440; -.
DR   OMA; KATKNMF; -.
DR   PhylomeDB; P19440; -.
DR   TreeFam; TF313608; -.
DR   BioCyc; MetaCyc:MONOMER66-34394; -.
DR   PathwayCommons; P19440; -.
DR   Reactome; R-HSA-174403; Glutathione synthesis and recycling.
DR   Reactome; R-HSA-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   Reactome; R-HSA-5423646; Aflatoxin activation and detoxification.
DR   Reactome; R-HSA-5579022; Defective GGT1 causes Glutathionuria (GLUTH).
DR   Reactome; R-HSA-9035968; Defective GGT1 causes Glutathionuria (GLUTH).
DR   Reactome; R-HSA-9664535; LTC4-CYSLTR mediated IL4 production.
DR   SABIO-RK; P19440; -.
DR   UniPathway; UPA00204; -.
DR   UniPathway; UPA00880; -.
DR   BioGRID-ORCS; 2678; 96 hits in 926 CRISPR screens.
DR   ChiTaRS; GGT1; human.
DR   GeneWiki; GGT1; -.
DR   GenomeRNAi; 2678; -.
DR   Pharos; P19440; Tbio.
DR   PRO; PR:P19440; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P19440; protein.
DR   Bgee; ENSG00000100031; Expressed in adult mammalian kidney and 117 other tissues.
DR   ExpressionAtlas; P19440; baseline and differential.
DR   Genevisible; P19440; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0036374; F:glutathione hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0102953; F:hypoglycin A gamma-glutamyl transpeptidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0103068; F:leukotriene C4 gamma-glutamyl transferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0002951; F:leukotriene-C(4) hydrolase; IDA:BHF-UCL.
DR   GO; GO:0000048; F:peptidyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0046222; P:aflatoxin metabolic process; TAS:Reactome.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0019344; P:cysteine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006631; P:fatty acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006536; P:glutamate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006750; P:glutathione biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006751; P:glutathione catabolic process; IDA:UniProtKB.
DR   GO; GO:1901750; P:leukotriene D4 biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006691; P:leukotriene metabolic process; IDA:UniProtKB.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0031179; P:peptide modification; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; IMP:UniProtKB.
DR   GO; GO:0002682; P:regulation of immune system process; ISS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IBA:GO_Central.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IBA:GO_Central.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0031638; P:zymogen activation; IDA:UniProtKB.
DR   Gene3D; 1.10.246.130; -; 1.
DR   Gene3D; 3.60.20.40; -; 1.
DR   InterPro; IPR043138; GGT_lsub_C.
DR   InterPro; IPR000101; GGT_peptidase.
DR   InterPro; IPR043137; GGT_ssub.
DR   InterPro; IPR029055; Ntn_hydrolases_N.
DR   PANTHER; PTHR11686; PTHR11686; 1.
DR   SUPFAM; SSF56235; SSF56235; 1.
DR   TIGRFAMs; TIGR00066; g_glut_trans; 1.
DR   PROSITE; PS00462; G_GLU_TRANSPEPTIDASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Alternative promoter usage;
KW   Alternative splicing; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Glutathione biosynthesis; Glycoprotein; Hydrolase;
KW   Lipid metabolism; Membrane; Mental retardation; Protease;
KW   Reference proteome; Sialic acid; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix; Zymogen.
FT   CHAIN           1..380
FT                   /note="Glutathione hydrolase 1 heavy chain"
FT                   /id="PRO_0000011058"
FT   CHAIN           381..569
FT                   /note="Glutathione hydrolase 1 light chain"
FT                   /evidence="ECO:0000269|PubMed:2907498"
FT                   /id="PRO_0000011059"
FT   TOPO_DOM        1..4
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P07314"
FT   TRANSMEM        5..26
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000250|UniProtKB:P07314"
FT   TOPO_DOM        27..569
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P07314"
FT   REGION          399..401
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   REGION          451..452
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   ACT_SITE        381
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:17924658,
FT                   ECO:0000269|PubMed:26013825"
FT   BINDING         107
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|PubMed:24047895"
FT   BINDING         423
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|PubMed:26013825"
FT   BINDING         474
FT                   /note="Glutamate; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:26013825"
FT   CARBOHYD        95
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20622017,
FT                   ECO:0000269|PubMed:24047895, ECO:0000269|PubMed:26013825"
FT   CARBOHYD        120
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17924658,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
FT                   ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   CARBOHYD        230
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   CARBOHYD        266
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17924658,
FT                   ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   CARBOHYD        297
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20622017"
FT   CARBOHYD        344
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17924658,
FT                   ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   CARBOHYD        511
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15084671,
FT                   ECO:0000269|PubMed:17924658, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:20622017, ECO:0000269|PubMed:24047895,
FT                   ECO:0000269|PubMed:26013825"
FT   DISULFID        50..74
FT                   /evidence="ECO:0000269|PubMed:24047895"
FT   DISULFID        192..196
FT                   /evidence="ECO:0000269|PubMed:24047895"
FT   VAR_SEQ         1..344
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7689219"
FT                   /id="VSP_008132"
FT   VAR_SEQ         341..366
FT                   /note="VVRNMTSEFFAAQLRAQISDDTTHPI -> ASSGVSAGGPQHDLRVLRCPAP
FT                   GPDL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1968061"
FT                   /id="VSP_001746"
FT   VAR_SEQ         367..569
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1968061"
FT                   /id="VSP_001747"
FT   VARIANT         51
FT                   /note="S -> L (in dbSNP:rs2330837)"
FT                   /id="VAR_025545"
FT   VARIANT         52
FT                   /note="K -> E (in dbSNP:rs2330838)"
FT                   /id="VAR_018373"
FT   VARIANT         177
FT                   /note="A -> V (in dbSNP:rs3895576)"
FT                   /id="VAR_018374"
FT   VARIANT         272
FT                   /note="V -> A (in dbSNP:rs4049829)"
FT                   /evidence="ECO:0000269|PubMed:1378736,
FT                   ECO:0000269|PubMed:1968061, ECO:0000269|PubMed:2563599,
FT                   ECO:0000269|PubMed:2568315, ECO:0000269|PubMed:2904146,
FT                   ECO:0000269|PubMed:2907498"
FT                   /id="VAR_018372"
FT   VARIANT         419
FT                   /note="N -> D (in dbSNP:rs17004876)"
FT                   /id="VAR_025546"
FT   VARIANT         435
FT                   /note="V -> A (in dbSNP:rs1062459)"
FT                   /id="VAR_049181"
FT   MUTAGEN         100
FT                   /note="K->N: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         102
FT                   /note="E->Q: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         107
FT                   /note="R->K: Reduces enzyme gamma-glutamyltranspeptidase
FT                   activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         107
FT                   /note="R->Q,H: Abolishes gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         108
FT                   /note="E->Q: Reduces gamma-glutamyltranspeptidase activity
FT                   by 98%."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         112
FT                   /note="R->Q: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         139
FT                   /note="R->Q: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         147
FT                   /note="R->Q: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         150
FT                   /note="R->Q: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8095045"
FT   MUTAGEN         192
FT                   /note="C->W: Loss of autocatalytic cleavage, cell membrane
FT                   localization and decrease in gamma-glutamyltranspeptidase
FT                   activity; when associated with Y-193."
FT                   /evidence="ECO:0000269|PubMed:23682772"
FT   MUTAGEN         193
FT                   /note="E->Y: Loss of autocatalytic cleavage, cell membrane
FT                   localization and decrease in gamma-glutamyltranspeptidase
FT                   activity; when associated with W-192."
FT                   /evidence="ECO:0000269|PubMed:23682772"
FT   MUTAGEN         383
FT                   /note="H->A: Reduces gamma-glutamyltranspeptidase activity
FT                   by 66%."
FT                   /evidence="ECO:0000269|PubMed:8827453"
FT   MUTAGEN         385
FT                   /note="S->A: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:7673200"
FT   MUTAGEN         413
FT                   /note="S->A: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:7673200"
FT   MUTAGEN         422
FT                   /note="D->A: Reduces enzyme gamma-glutamyltranspeptidase
FT                   activity by 90%."
FT                   /evidence="ECO:0000269|PubMed:7759490"
FT   MUTAGEN         423
FT                   /note="D->A: Abolishes gamma-glutamyltranspeptidase
FT                   activity. Increases KM for D-gamma-glutamyl-p-nitroanalide
FT                   by over 1000-fold."
FT                   /evidence="ECO:0000269|PubMed:7759490"
FT   MUTAGEN         425
FT                   /note="S->A: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:7673200"
FT   MUTAGEN         451
FT                   /note="S->A: Reduces gamma-glutamyltranspeptidase activity
FT                   by 99%. Abolishes activity; when associated with A-452."
FT                   /evidence="ECO:0000269|PubMed:7673200"
FT   MUTAGEN         452
FT                   /note="S->A: Reduces gamma-glutamyltranspeptidase activity
FT                   by 99%. Abolishes activity; when associated with A-451."
FT                   /evidence="ECO:0000269|PubMed:7673200"
FT   MUTAGEN         454
FT                   /note="C->A: No effect on gamma-glutamyltranspeptidase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:7759490"
FT   MUTAGEN         505
FT                   /note="H->A: Reduces gamma-glutamyltranspeptidase activity
FT                   by 90%."
FT                   /evidence="ECO:0000269|PubMed:8827453"
FT   MUTAGEN         545
FT                   /note="Q->K: Reduces enzyme activity by 97%."
FT                   /evidence="ECO:0000269|PubMed:24047895"
FT   CONFLICT        30..31
FT                   /note="SK -> KS (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        47
FT                   /note="A -> K (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        139
FT                   /note="R -> E (in Ref. 5; AAA35889)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="A -> S (in Ref. 10; AAI28240)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        361
FT                   /note="D -> H (in Ref. 10; AAI28240)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        372
FT                   /note="E -> D (in Ref. 7; AAA02886)"
FT                   /evidence="ECO:0000305"
FT   STRAND          36..40
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           48..59
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           64..78
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   TURN            79..82
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          87..95
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   TURN            96..99
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          100..106
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           122..126
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           129..131
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           137..148
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           153..166
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           172..180
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           182..187
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           189..195
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          206..208
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           211..223
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           226..229
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           234..243
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           250..255
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          259..263
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          265..269
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          272..276
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           283..294
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           300..303
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           306..327
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   TURN            333..335
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           339..345
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           348..355
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           366..369
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          382..387
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          393..399
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   TURN            403..406
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          407..409
FT                   /evidence="ECO:0007829|PDB:4ZC6"
FT   TURN            411..413
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           420..423
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          427..429
FT                   /evidence="ECO:0007829|PDB:5V4Q"
FT   STRAND          432..434
FT                   /evidence="ECO:0007829|PDB:4Z9O"
FT   HELIX           439..441
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          456..460
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          465..476
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           477..489
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           495..500
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          508..511
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          513..515
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   HELIX           521..529
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          534..536
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          543..550
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   STRAND          553..557
FT                   /evidence="ECO:0007829|PDB:4GDX"
FT   TURN            560..562
FT                   /evidence="ECO:0007829|PDB:4GDX"
SQ   SEQUENCE   569 AA;  61410 MW;  71AE12485239A69F CRC64;
     MKKKLVVLGL LAVVLVLVIV GLCLWLPSAS KEPDNHVYTR AAVAADAKQC SKIGRDALRD
     GGSAVDAAIA ALLCVGLMNA HSMGIGGGLF LTIYNSTTRK AEVINAREVA PRLAFATMFN
     SSEQSQKGGL SVAVPGEIRG YELAHQRHGR LPWARLFQPS IQLARQGFPV GKGLAAALEN
     KRTVIEQQPV LCEVFCRDRK VLREGERLTL PQLADTYETL AIEGAQAFYN GSLTAQIVKD
     IQAAGGIVTA EDLNNYRAEL IEHPLNISLG DVVLYMPSAP LSGPVLALIL NILKGYNFSR
     ESVESPEQKG LTYHRIVEAF RFAYAKRTLL GDPKFVDVTE VVRNMTSEFF AAQLRAQISD
     DTTHPISYYK PEFYTPDDGG TAHLSVVAED GSAVSATSTI NLYFGSKVRS PVSGILFNNE
     MDDFSSPSIT NEFGVPPSPA NFIQPGKQPL SSMCPTIMVG QDGQVRMVVG AAGGTQITTA
     TALAIIYNLW FGYDVKRAVE EPRLHNQLLP NVTTVERNID QAVTAALETR HHHTQIASTF
     IAVVQAIVRT AGGWAAASDS RKGGEPAGY
//
